Synopsis of recent research by authors named "Zhankui Xu"
- Zhankui Xu's recent research primarily focuses on the comparative efficacy of different antiplatelet therapies in patients with minor strokes or transient ischemic attacks (TIAs), particularly those with genetic factors such as loss-of-function alleles.
- In the 2023 article, Xu conducted a prespecified analysis of the CHANCE-2 trial, assessing the benefits of ticagrelor-aspirin versus clopidogrel-aspirin in diverse etiologies of minor strokes and TIAs, emphasizing the need to evaluate treatment effectiveness based on stroke cause.
- A 2021 trial led by Xu highlighted the lack of prior research comparing ticagrelor and clopidogrel in loss-of-function allele carriers, providing valuable insights from a large randomized study that could influence future guidelines for secondary stroke prevention in this specific patient demographic.
